Teitur Trophics

The company's business model is centered on the research and clinical development of its drug candidates. The primary product is a platform of first-in-class cyclic peptides. Its lead drug candidate, TT-P34, is administered subcutaneously and targets key pathological hallmarks of neurodegeneration, including mitochondrial failure, lysosomal dysfunction, and the loss of pro-survival signaling. It works to restore energy homeostasis in brain cells and induce the clearance of toxic protein aggregates, thereby promoting neuronal survival. The company has also secured a Eurostars grant for a project called RE-HEAR, which aims to develop peptide-based therapeutics for sensorineural hearing loss.

Teitur Trophics operates in the biotech market, focusing on developing novel drugs to address significant unmet medical needs. The company secured seed funding from the BioInnovation Institute in 2020. In March 2023, it raised €28 million in a Series A financing round co-led by Sunstone Life Science Ventures and Sound Bioventures, with participation from other investors. This capital is intended to advance TT-P34 into clinical development, including a Phase 1b study, and to progress its pipeline of other peptide compounds.